Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement in the US over a patent infringement lawsuit regarding generic Ozempic, a drug used for blood sugar and weight loss.
Illustration: Uttam Ghosh/Rediff.com
New Delhi, Oct 7 (PTI) NATCO Pharma Ltd on Monday said its partner Mylan Pharmaceuticals Inc has reached a patent litigation settlement with Novo Nordisk in the US over generic Ozempic, a drug used to lower blood sugar and weight loss.
NATCO and Mylan have partnered for the development of generic Ozempic (Semaglutide) products, the company said in a regulatory filing.
Ozempic is a prescription medication patented by Novo Nordisk.
"Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide)," NATCO said in the filing.
The terms of the settlement are confidential, it added.
Novo Nordisk had filed a patent infringement suit against Mylan over Ozempic in a US court.
Home » Market News » Mylan Settles Patent Suit with Novo Nordisk over Generic Ozempic
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback